shr-a2009
mAbexperimentalADC
Clinical trial activity
9 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2021 (NCT05114759)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07183189 | Phase 3 | Oct 31, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06671379 | Phase 3 | Nov 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06649331 | Phase 2 | Oct 21, 2024 | Fudan University |
| NCT06465238 | Phase 2 | Jun 30, 2024 | Henan Medical University |
| NCT06474455 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT06222879 | Phase 1/Phase 2 (Phase 2) | Feb 20, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06092268 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2023 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05394818 | Phase 1 | Jul 21, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05114759 | Phase 1 | Dec 1, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 6 | 6 | 3 | 2021 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1